VICL Vical Incorporated

2.25
+0  (7%)
Previous Close 2.10
Open 2.13
Price To book 0.51
Market Cap 24.97M
Shares 11,093,000
Volume 104,846
Short Ratio 1.31
Av. Daily Volume 124,063

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 2Q 2018.
VCL-HB01
HSV-2 therapeutic vaccine
Phase 2 data released September 19, 2016 did not meet primary endpoint.
ASP0113 Vaccine
Kidney transplant recipients
Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018.
HSV-2 Therapeutic Vaccine
Genital Herpes in Adults
Data did not meet primary endpoint
Vaxfectin-formulated therapeutic vaccine
Herpes
Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q 2018.
ASP0113 Vaccine
Hematopoietic cell transplant recipients